NCT04034628

Brief Summary

Peritoneal dialysis (PD) is actively promoted as the preferred form of dialysis for patients with kidney failure. However, 1 in 5 patients will experience a signification catheter insertion-related PD catheter complication in the first 6 months following insertion. Little is known about the patient-, operator-, and center-level factors that influence PD catheter complications. There is a need to identify key modifiable practices to focus randomized trials and quality improvement efforts. We will leverage prior funding, a custom-built data collection platform, pilot data, and a group of engaged stakeholders, partners, and knowledge users to: a) Determine if method of insertion is associated with PD catheter complications b) Identify operator/center characteristics and practices associated with PD catheter complications c) Use a data-driven approach to achieve expert consensus on optimal practices for PD catheter insertion and care.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,320

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 24, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 26, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2019

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2024

Completed
Last Updated

July 26, 2019

Status Verified

July 1, 2019

Enrollment Period

3.3 years

First QC Date

July 24, 2019

Last Update Submit

July 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Insertion related complications

    Complications (exit site leak, flow restriction, pain, infection, bleeding) likely associated with the method of insertion

    1 year following the start of PD therapy

Study Arms (2)

Laparoscopic insertion

Individuals who undergo laparoscopic PD catheter insertion

Device: Peritoneal Catheter Insertion - LaparoscopicDevice: Peritoneal Catheter Insertion - Percutaneous

Percutaneous insertion

Individuals who undergo percutaneous PD catheter insertion by either a nephrologist or radiologist.

Device: Peritoneal Catheter Insertion - LaparoscopicDevice: Peritoneal Catheter Insertion - Percutaneous

Interventions

Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure

Laparoscopic insertionPercutaneous insertion

Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure

Laparoscopic insertionPercutaneous insertion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We will identify all patients undergoing their first PD catheter insertion during the study period, at 20 participating centers in Canada and the USA (see Appendix 1). A total of 800 cases have been captured to date during our pilot study and an additional 1,520 cases will be accrued over a 30-month period, for a total sample size of 2,320 PD catheter insertions. We will attempt to collect information about consecutive patients undergoing PD catheter attempts/insertions in order to accurately measure local performance. However if a waiver of consent cannot be obtained at participating centers, then non-consecutive patients will be enrolled

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N1A4, Canada

Location

Study Officials

  • Matthew Oliver, MD MHS

    University of Toronto

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 24, 2019

First Posted

July 26, 2019

Study Start

September 1, 2019

Primary Completion

December 31, 2022

Study Completion

March 30, 2024

Last Updated

July 26, 2019

Record last verified: 2019-07

Locations